OPL 4.35% 2.4¢ opyl limited

Opyl is claiming credit for predicting a positive interim...

  1. 1,185 Posts.
    lightbulb Created with Sketch. 591
    Opyl is claiming credit for predicting a positive interim outcome of the $DXB/Dimerix ACTION3 Phase 3 trial of DMX-200 in FSGS Kidney Disease.

    Bernice Averion, Medtech Marketing Marketing Manager of OPL's TrialKey business:

    "...Opyl foresaw this success, predicting a high probability of 74.51% even before the official results were revealed.

    "As a result, DXB's share price has experienced a notable surge, underlining the potential benefits of predictive tools like TrialKey for investors.

    "Imagine having the foresight to spot viable investments before the market catches on!"
 
watchlist Created with Sketch. Add OPL (ASX) to my watchlist
(20min delay)
Last
2.4¢
Change
0.001(4.35%)
Mkt cap ! $4.097M
Open High Low Value Volume
2.4¢ 2.4¢ 2.4¢ $2.384K 99.33K

Buyers (Bids)

No. Vol. Price($)
1 50000 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.5¢ 40003 1
View Market Depth
Last trade - 15.35pm 04/10/2024 (20 minute delay) ?
OPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.